ClinicalTrials.gov record
Withdrawn Phase 1Phase 2 Interventional

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

ClinicalTrials.gov ID: NCT00085449

Public ClinicalTrials.gov record NCT00085449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells

Study identification

NCT ID
NCT00085449
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Enrollment
Not listed

Conditions and interventions

Interventions

  • alemtuzumab Biological
  • cyclosporine Drug
  • fludarabine phosphate Drug
  • melphalan Drug
  • mycophenolate mofetil Drug
  • peripheral blood stem cell transplantation Procedure
  • radiation therapy Radiation

Biological · Drug · Procedure + 1 more

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2006
Primary completion
Dec 31, 2006
Completion
Dec 31, 2006
Last update posted
Nov 26, 2019

2006 – 2007

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
22
Facility City State ZIP Site status
Moores UCSD Cancer Center La Jolla California 92093-0658
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center Los Angeles California 90048
UCSF Comprehensive Cancer Center San Francisco California 94115
CCOP - Christiana Care Health Services Newark Delaware 19713
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C. District of Columbia 20007
University of Chicago Cancer Research Center Chicago Illinois 60637-1470
Holden Comprehensive Cancer Center at University of Iowa Iowa City Iowa 52242-1009
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston Massachusetts 02115
University of Minnesota Cancer Center Minneapolis Minnesota 55455
Siteman Cancer Center at Barnes-Jewish Hospital St Louis Missouri 63110
UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha Nebraska 68198-7680
St. Joseph's Hospital and Medical Center Paterson New Jersey 07503
Roswell Park Cancer Institute Buffalo New York 14263-0001
Don Monti Comprehensive Cancer Center at North Shore University Hospital Manhasset New York 11030
Memorial Sloan-Kettering Cancer Center New York New York 10021
Mount Sinai Medical Center New York New York 10029
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill North Carolina 27599-7295
Duke Comprehensive Cancer Center Durham North Carolina 27710
Wake Forest University Comprehensive Cancer Center Winston-Salem North Carolina 27157-1082
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Columbus Ohio 43210-1240
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital Pittsburgh Pennsylvania 15224
Hollings Cancer Center at Medical University of South Carolina Charleston South Carolina 29425
Virginia Commonwealth University Massey Cancer Center Richmond Virginia 23298-0037

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00085449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 26, 2019 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00085449 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →